A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation

Thorax

Volumn 70, Issue 5, 2015, Pages 442-450

  Corris, Paul A ^a,b   Ryan, Victoria A ^b   Small, Therese ^a   Lordan, James ^a   Fisher, Andrew J ^a,b   Meachery, Gerard ^a   Johnson, Gail ^a   Ward, Chris ^b  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; AZITHROMYCIN; CYCLOSPORIN A; PLACEBO; PREDNISOLONE; TACROLIMUS; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; ASPERGILLUS FUMIGATUS; BRONCHIOLITIS OBLITERANS; CANDIDA; CANDIDA ALBICANS; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; MALE; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RALSTONIA PICKETTII; RANDOMIZED CONTROLLED TRIAL; STENOTROPHOMONAS MALTOPHILIA; TREATMENT OUTCOME; ADVERSE EFFECTS; MIDDLE AGED; SYNDROME;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHIOLITIS OBLITERANS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; SYNDROME; TREATMENT OUTCOME;

EID: 84929461304     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-205998     Document Type: Article

References (41)

1. Arcasoy SM, Kotloff RM. Lung transplantation. N Engl J Med 1999;340:1081-91.
2. Rutherford RM, Fisher AJ, Hilton C, et al. Functional status and quality of life in patients surviving 10 years after lung transplantation. Am J Transplant 2005;5:1099-104.
3. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002;21:297-310.
4. Diamond JM, Lee JC, Kawut SM, et al. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2013;187:527-34.
5. Vanaudenaerde BM, Meyts I, Vos R, et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 2008;32:832-43.
6. Todd JL, Palmer SM. Bronchiolitis obliterans syndrome: the final frontier for lung transplantation. Chest 2011;140:502-8.
7. Christie JD, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant 2010;29: 1104-18.
8. Fisher AJ, Rutherford RM, Bozzino J, et al. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2005;5:537-43.
9. Gerhardt SG, McDyer JF, Girgis RE, et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003;168:121-5.
10. Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004;77:1465-7.
11. Yates B, Murphy DM, Forrest IA, et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005;172:772-5.
12. Gottlieb J, Szangolies J, Koehnlein T, et al. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008;85:36-41.
13. Jain R, Hachem RR, Morrell MR, et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant 2010;29:531-7.
14. Shitrit D, Bendayan D, Gidon S, et al. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 2005;24:1440-3.
15. Porhownik NR, Batobara W, Kepron W, et al. Effect of maintenance azithromycin on established bronchiolitis obliterans syndrome in lung transplant patients. Can Respir J 2008;15:199-202.
16. Benden C, Boehler A. Long-term clarithromycin therapy in the management of lung transplant recipients. Transplantation 2009;87:1538-40.
17. Williams TJ, Verleden GM. Azithromycin: a plea for multicenter randomized studies in lung transplantation. Am J Respir Crit Care Med 2005;172:657-9.
18. Corris P, Small T, Ryan V, et al. A Randomised Controlled Trial Of Azithromycin Therapy In Bronchiolitis Obliterans Syndrome (BOS) Post Lung Transplantation. Am J Respir Crit Care Med 2012;315:A5324.
19. Corris PA, Small T, Ryan VA, et al. 173 A randomised controlled trial of azithromycin therapy in Bronchiolitis Obliterans Syndrome (BOS) post lung transplantation. J Heart Lung Transplant 2012;31:S67.
20. Forrest IA, Murphy DM, Ward C, et al. Primary airway epithelial cell culture from lung transplant recipients. Eur Respir J 2005;26:1080-5.
21. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007;26:1229-42.
22. Steele F. Multilevel models for longitudinal data. J R Stat Soc Ser A Stat Soc 2008;171:5-19.
23. Rasbash J, Browne W, Healey W, et al. MLwiN Version 2.28. London: Institute of Education, Multilevel Models Project, 2013.
24. Senn S. Change from baseline and analysis of covariance revisited. Stat Med 2006;25:4334-44.
25. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
26. Vos R, Vanaudenaerde BM, Verleden SE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 2011;37:164-72.
27. Burns GP. Respiratory medicine. In: Bourke SJ, Burns GP, eds. Respiratory medicine lecture notes. UK: Wiley Blackwell, 2011:6-7.
28. Contoli M, Bousquet J, Fabbri LM, et al. The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy 2010;65:141-51.
29. Chacon RA, Corris PA, Dark JH, et al. Tests of airway function in detecting and monitoring treatment of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 2000;19:263-9.
30. Ward C, Snell GI, Zheng L, et al. Endobronchial biopsy and bronchoalveolar lavage in stable lung transplant recipients and chronic rejection. Am J Respir Crit Care Med 1998;158:84-91.
31. Kelly C, Ward C, Stenton CS, et al. Number and activity of inflammatory cells in bronchoalveolar lavage fluid in asthma and their relation to airway responsiveness. Thorax 1988;43:684-92.
32. DiGiovine B, Lynch JP III, Martinez FJ, et al. Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. J Immunol 1996;157:4194-202.
33. Verleden GM, Vos R, De Vleeschauwer SI, et al. Obliterative bronchiolitis following lung transplantation: from old to new concepts? Transpl Int 2009;22:771-9.
34. Murphy DM, Forrest IA, Curran D, et al. Macrolide antibiotics and the airway: antibiotic or non-antibiotic effects? Expert Opin Investig Drugs 2010;19:401-14.
35. Griffin SM, Robertson AG, Bredenoord AJ, et al. Aspiration and allograft injury secondary to gastroesophageal reflux occur in the immediate post-lung transplantation period (prospective clinical trial). Ann Surg 2013;258:705-11; discussion 11-2.
36. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010;23: 590-615.
37. Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011;121:3554-63.
38. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-90.
39. Leitner JM, Graninger W, Thalhammer F. Hepatotoxicity of antibacterials: Pathomechanisms and clinical. Infection 2010;38:3-11.
40. Verleden GM, Vanaudenaerde BM, Dupont LJ, et al. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006;174:566-70.
41. Forrest IA. The potential role of matrix metalloproteinases and their inhibitors in obliterative bronchiolitis following lung transplantation. PhD thesis. UK: Newcastle University, 2009.